Novel implant for macular telangiectasia gains fast-track designation
The FDA has fast-tracked Neurotech’s implant for stalling central vision loss in people with type 2 macular telangiectasia. Source: AAO
- Posted on: Feb 15 2019
- Leave a response
The FDA has fast-tracked Neurotech’s implant for stalling central vision loss in people with type 2 macular telangiectasia. Source: AAO
Researcher compared foveal vascular anatomy in patients with and without disorganization of retinal inner layers using OCT angiography. Source: AAO
In this study, the authors document the development of optic disc edema in participants who were placed on strict head-down tilt bed rest in a mild hypercapnic environment. Source: AAO
This paper evaluated the locations, circumstances and outcomes of glaucoma patients’ falls. Source: AAO
This phase 2 study reports the use of a high-dose gene therapy for choroideremia. Source: AAO
This week, a micro-therapeutic formulation of atropine enters phase 3 trials, Genentech uses virtual reality to train retinal surgeons and an endangered okapi calf undergoes surgery to remove a corneal lesion. Source: AAO
This recommendation statement by the U.S. Preventive Services Task Force reaffirms the need for ocular prophylaxis of newborns with 0.5% erythromycin ophthalmic ointment. Source: AAO
Researchers compared the visual outcomes and complications relating to 2 techniques: nanothin Descemet stripping automated endothelial keratoplasty (NT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK). Source: AAO
In this paper, researchers assessed the association between migraines with visual aura and atrial fibrillation (AF). Source: AAO
Investigators compared refractive outcomes of topography-guided LASIK treatment based on anterior corneal astigmatism (ACA) versus manifest refractive astigmatism. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »